Chelohart®
ods of treatment, were prescribed a course of CHELOHART®, 1 capsule 2 times a day with meals for
30 days.
The control group consisted of 10 patients (6 men aged 47 to 66 years and 4 women aged 50 to 69
years) who were prescribed only conventional treatment: long-acting nitrates, β-blockers, corinfar,
corvalol, motherwort tincture, and other sedatives (2, 3).
RESEARCH METHODS
The study of the effectiveness of the use of CHELOHART® was carried out based on generally accept-
ed research methods. Patients’ complaints were assessed in dynamics, general clinical and biochemical
blood tests, ultrasound examination of the heart, electrocardiography, a dosed exercise test on a bicycle
ergometer were carried out according to the method of step-by-step increasing intermittent activity.
RESEARCH RESULTS
The study results of the dynamics of changes in subjective indicators showed that in patients taking
CHELOHART®, the number of complaints about the general condition, shortness of breath, recurring
pain in the heart, and a feeling of rapid heartbeat decreased. The frequency and duration of angina
attacks significantly reduced. In 56% of patients, it was possible to reduce by half the daily dose of
nitrates of prolonged action against the background of a persistent decrease in the attacks of chest
pain in comparison with the initial level before treatment (Table 1).
Dynamics of subjective indicators in patients with coronary heart disease. Table 1
Complaints Patient Groups
After treatment with conventional means, After treatment with CHELOHART®, abs. (%)
abs. (%)
Improvement Without Improvement Without
Improvements Improvements
Recurrent pain in the heart region 4 (40%) 6 (60%) 15 (68,2%)* 7 (31,8%)*
Dyspnea 6 (60%) 4 (40%) 16 (72,7%)* 6 (27,3%)*
Weakness 7 (70%) 3 (30%) 16 (72,7%)* 6 (27,3%)*
Dizziness 6 (60%) 4 (40%) 12 (54,5%) 10 (45,5%)
Headaches 5 (50%) 5 (50%) 15 (68,2%)* 7 (31,8%)*
Noise in ears 5 (50%) 5 (50%) 14 (63,6%) 8 (36,4%)
Palpitations 6 (60%) 4 (40%) 17 (77,3%)* 5 (22,7%)*
* p <0.05 compared with the indicator in patients after treatment with conventional means.
The study of the dynamics of changes in mineral metabolism showed that in patients of both groups,
the potassium content in the blood plasma and calcium in the blood serum increased, approaching
normal values. There was no significant difference in indicators in patients of the primary and control
groups. However, the indicators after treatment were better in patients of the primary group who took
CHELOHART®than in patients in the control group. The magnesium content in the blood serum re-
mained within the normal range before and after treatment in patients of both groups (Table 2).
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.